80 CHF CHF 80.00
BVT-0307-M0011 mgCHF 80.00
BVT-0307-M0055 mgCHF 290.00
BVT-0307-M02525 mgCHF 1'010.00
|Synonyms||NSC234714; BRN4689958; ICI69653|
|Merck Index||14: 727|
|Source/Host Chemicals||Isolated from Phoma sp. BS 7210.|
|Purity Chemicals||≥98% (HPLC)|
|Appearance||White to off-white solid.|
|Solubility||Soluble in DMSO (50 mg/ml), methanol (10 mg/ml) or 100% ethanol; insoluble in water.|
|Identity||Determined by 1H-NMR.|
|Declaration||Manufactured by BioViotica.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||+4°C|
|Handling Advice||Protect from light when in solution.|
Stable for at least 1 year after receipt when stored at +4°C.
After reconstitution protect from light at -20°C.
|Product Specification Sheet|
- Antiviral and antineoplastic agent.
- Antileishmanial agent.
- Reversible inhibitor of eukaryotic nuclear DNA replication.
- Useful for cell synchronization.
- Blocks the cell cycle at G1/S phase.
- Prolongs the half life of DNA methyltransferase. DNA methylation/demethylation modulator.
- Specific DNA polymerase α and δ inhibitor in eukaryotic cells and in some viruses of animal origin.
- Acts synergistically with vincristine and doxorubicin.
- Apoptosis inhibitor/inducer.
- X-Ray crystallographic determination of the structure of the antibiotic aphidicolin: a tetracyclicditerpenoid containing a new ring system: K.M. Brundret, et al.; J. C. S. Chem. Commun. 1027 (1972)
- Aphidicolin prevents mitotic cell division by interfering with the activity of DNA polymerase-alpha: S. Ikegami, et al.; Nature 275, 458 (1978)
- New views of the biochemistry of eucaryotic DNA replication revealed by aphidicolin, an unusual inhibitor of DNA polymerase alpha: J.A. Huberman; Cell 23, 647 (1981)
- Aphidicolin: a specific inhibitor of nuclear DNA replication in eukaryotes: S. Spadari, et al.; TIBS 7, 29 (1982)
- Aphidicolin potentiates apoptosis induced by arabinosyl nucleosides in human myeloid leukemia cell lines: K. Kuwakado, et al.; Biochem. Pharmacol. 46, 1909 (1993)
- Dissociation of nuclear and cytoplasmic cell cycle progression by drugs employed in cell synchronization: L. Urbani, et al.; Exp. Cell. Res. 219, 159 (1995)
- Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3: M.M. Borner, et al.; Cancer Res. 55, 2122 (1995)
- TrkA neurogenic receptor regulates differentiation of neuroblastoma cells: W. Poluha, et al.;Oncogene10, 185 (1995)
- Effect of aphidicolin on DNA methyltransferase in the nucleus: I. Suetake, et al.; Cell Struct. Funct. 23, 137 (1998)
- Cytotoxicity of aphidicolin and its derivatives against neuroblastoma cells in vitro: synergism with doxorubicin and vincristine: M. Michaelis, et al.; Anticancer Drugs 11, 479 (2000)
- Antileishmanial activities of aphidicolin and its semisynthetic derivatives: O. Kayser, et al.; Antimicrob. Agents Chemother. 45, 288 (2001)
- Aphidicolin and bleomycin induced chromosome damage as biomarker of mutagen sensitivity: a twin study: B. Tedeschi, et al.; Mutat. Res. 546, 55 (2004)
- Human papillomavirus episome stability is reduced by aphidicolin and controlled by DNA damage response pathways: T. G. Edwards, et al.; J. Virol. 87, 3979 (2013)
- Aphidicolin-induced nuclear elongation in tobacco BY-2 cells: H. Yashura, et al.; Plant Cell Physiol. 55, 913 (2014)
- Active and passive demethylation of male and female pronuclear DNA in the mammalian zygote: F. Guo, et al.; Cell Stem Cell 15, 447 (2014)
- Structural basis for inhibition of DNA replication by aphidicolin: A.G. Baranovskiy, et al.; Nucl. Acids Res. 42, 14013 (2014)
- Toward a cancer drug of fungal origin: A. Kornienko, et al.; Med. Res. Rev. 35, 937 (2015)
- Aphidicolin: its chemistry and biosynthesis: J.R. Hanson; J. Chem. Res. 42, 395 (2018)
- Stability of cytoplasmic nanoviscosity during cell cycle of HeLa cells synchronized with Aphidicolin: K. Szczepanski, et al.; Sci. Rep. 9, 1 (2019)
- Mitotic DNA synthesis is differentially regulated between cancer and noncancerous cells: C.L. Graber-Feesl, et al.; Mol. Cancer Res. 17, 1687 (2019)